We next evaluated whether lymphoma-intrinsic MYC could suppress the activity of effector T-cells by comparing their cytokine release after T-cell engager blinatumomab-mediated cytotoxicity against parental OCI-LY18 WT versus MYC downregulated cells. The gene discussed is MYC; the disease is lymphoma.